UNIONDALE, NY, Oct. 24, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and consumer products company, today announced that it will be participating in the ThinkEquity Conference on October 30, 2025, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies. Ted Karkus ...

Financial Performance & Restructuring - ProPhase Labs sold Pharmaloz Manufacturing for $23.6 million[11] - The company shut down the genomics laboratory, saving over $6 million per year[11] - ProPhase Labs is targeting over $50 million in net near-term cash recovery from COVID-19 receivables through an initiative with Crown Medical Collections[13, 15, 94] BE-Smart Esophageal Cancer Diagnostic - The BE-Smart test achieved greater than a 95% technical success rate in a key validation study, confirming its ability to reliably detect biomarkers[36, 95] - The total potential addressable market for the BE-Smart test is estimated at ~$7 billion - $14 billion[27] - The annual incidence change of Esophageal Adenocarcinoma (EAC) was 766.67% higher in 2017 compared to 1973[25] DNA Complete & Nebula Genomics - DNA Complete was launched on November 4, 2024, offering whole genome sequencing[11, 47] - DNA Complete analyzes virtually 100% of DNA, compared to less than 1% analyzed by typical DNA Ancestry tests[47] Equivir Dietary Supplement - Preliminary results from Equivir clinical trials showed that 37.7% of patients in the Equivir group acquired a viral infection versus 62.3% in the placebo group[78] - After 4 days of illness, only 3% of the Equivir group still had mild symptoms vs 55% in the placebo group[79]